What is Xeloda
Approved as Treatment by the FDA
Capecitabine, otherwise known as Xeloda, is approved by the FDA for 10 uses including Stage III Colon Cancer and Colorectal Carcinoma .Effectiveness
When to interrupt dosage
The proposed dosage of Xeloda depends upon the diagnosed affliction, such as Pancreatic Metastatic Cancer, Malignant Neoplasms and Esophageal Cancer. The prescribed amount of dosage is contingent upon the technique of delivery (e.g. Tablet or Tablet, film coated - Oral) listed in the table underneath.Warnings
Xeloda ContraindicationsXeloda Novel Uses: Which Conditions Have a Clinical Trial Featuring Xeloda?
Currently, 337 active clinical trials are assessing the potential of Xeloda to manage Duke's C Colon cancer, Pancreatic Endocrine Carcinoma and refractory peritoneal cancer.Xeloda Reviews: What are patients saying about Xeloda?
Patient Q&A Section about xeloda
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Xeloda a chemo pill?
"Capecitabine is a chemotherapy drug, also known by its chemical name, Xeloda. It belongs to a class of drugs known as antimetabolites, which also includes other chemotherapy drugs such as Fluorouracil, Gemzar, and Methotrexate."
What type of cancer does Xeloda treat?
"Xeloda is a chemotherapy medication used in combination with other cancer treatments. It is most often used to treat breast cancer that has stopped responding to other chemotherapy drugs."
What does Xeloda do to your body?
"XELODA can lead to heart problems, such as: a heart attack, reduced blood flow to the heart, chest pain, irregular heartbeats, changes in the electrical activity of your heart as seen on an electrocardiogram (ECG), problems with your heart muscle, heart failure, and sudden death."
What are the long term side effects of Xeloda?
"The long-term effects of taking Xeloda can include developing heart problems or kidney failure, which could last for a long time or be permanent. Xeloda may also cause a permanent loss of fertility."